Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ortivus ABOSTO:ORTI A 44 EV-to-FCF is -6.94 as of Aug. 20, 2026. GuruFocus rates OSTO:ORTI A with a GF Score™ of 44/100 and a GF Value™ of kr2.44 (Fairly Valued). The stock has 3 warning signs investors should review. Among 407 Medical Devices & Instruments companies, Ortivus AB ranks worse than 245700% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ortivus AB's Enterprise Value is kr192.36 Mil.
Ortivus AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr-27.73 Mil. Therefore, Ortivus AB's EV-to-FCF for today is -6.94.
The historical rank and industry rank for Ortivus AB's EV-to-FCF or its related term are showing as below:
OSTO:ORTI A'
s EV-to-FCF Range Over the Past 10 Years
Min: -8715.48 Med: -13.19 Max: 292.54
Current: -6.94
During the past 13 years, the highest EV-to-FCF of Ortivus AB was 292.54. The lowest was -8715.48. And the median was -13.19.
OSTO:ORTI A's EV-to-FCF is ranked worse than 100% of 407
companies
in the Medical Devices & Instruments industry
Industry Median: 24.75
vs OSTO:ORTI A: -6.94
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ortivus AB's share price for today is kr2.36.
Ortivus AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.400.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Ortivus AB EV-to-FCF Related Terms
Ortivus AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Ortivus AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ORTI A vs ISRG, BDX, MDLN: EV-to-FCF Comparison
For the Medical Instruments & Supplies subindustry, Ortivus AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ortivus AB EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ortivus AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Ortivus AB's EV-to-FCF falls into.
Ortivus AB's current Enterprise Value is kr192.36 Mil.
Ortivus AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-27.73 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ortivus AB (OSTO:ORTI A) has a EV-to-FCF of -6.94 as of Aug. 20, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ortivus AB and its competitors. According to the industry distribution chart, Ortivus AB ranks #999999 out of 407 companies in the Medical Devices & Instruments industry.
Is Ortivus AB's EV-to-FCF too high?
Ortivus AB's current EV-to-FCF is -6.94. Based on the distribution chart, Ortivus AB ranks #999999 out of 407 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Ortivus AB has a GF Score™ of 44/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ortivus AB's EV-to-FCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Ortivus AB ranks #999999 out of 407 companies for EV-to-FCF. This places Ortivus AB in the lower half of its industry. The industry median EV-to-FCF is 24.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 24.75, based on 407 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ortivus AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 24.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ortivus AB's current EV-to-FCF is -6.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ortivus AB stock overvalued right now?
Based on GuruFocus' analysis, Ortivus AB (OSTO:ORTI A) is currently considered Fairly Valued. The stock's GF Value™ is kr2.44, compared to a current price of kr2.36 — trading 3.3% below its estimated fair value. The current EV-to-FCF is -6.94. Ortivus AB's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Ortivus AB (OSTO:ORTI A), the current EV-to-FCF is -6.94 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ortivus AB (OSTO:ORTI A) Overvalued in 2026?
Based on GuruFocus' analysis, Ortivus AB stock appears to be undervalued.
The current stock price of kr2.36 is trading 3.3% below its estimated GF Value™ of kr2.44.
GuruFocus considers Ortivus AB to be Fairly Valued.
Key valuation signals for OSTO:ORTI A:
EV-to-FCF: -6.94
GF Value™: kr2.44 vs. price of kr2.36 (3.3% below fair value)
No single metric tells the full story. See the OSTO:ORTI A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ortivus AB is a supplier of mobile solutions for modern emergency medical care. The company has developed an user-friendly solutions that supports diagnostics, increase efficiency, and deliver long-term cost savings for healthcare providers. By integrating its solutions with electronic health records, dispatch systems, and national registries, the company ensures fast and secure information management and more integrated care process. Its product portfolio includes MobiMed ePR, MobiMed Monitor, MobiMed FleetCtrl, MobiMed Life, and others.
44GF Score
Get the complete analysis for OSTO:ORTI A
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ORTI A has been successfully added to your 
